Repligen Co. (NASDAQ:RGEN) Shares Sold by US Bancorp DE

US Bancorp DE lessened its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 34.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,032 shares of the biotechnology company's stock after selling 5,261 shares during the quarter. US Bancorp DE's holdings in Repligen were worth $1,493,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank boosted its holdings in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock valued at $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after buying an additional 89 shares in the last quarter. Ballentine Partners LLC boosted its position in Repligen by 6.2% in the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after buying an additional 105 shares during the period. Diversified Trust Co grew its stake in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after purchasing an additional 106 shares in the last quarter. Finally, CWM LLC increased its holdings in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 114 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on RGEN. Stephens reissued an "overweight" rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. UBS Group cut their target price on Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. Benchmark restated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $190.25.

Repligen Trading Down 1.4 %

Shares of RGEN stock opened at $143.88 on Friday. The company has a market capitalization of $8.06 billion, a P/E ratio of -3,596.10, a price-to-earnings-growth ratio of 4.01 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The business's 50 day moving average is $141.77 and its two-hundred day moving average is $145.51. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.